SCHEMBL951158

SCHEMBL951158

COC(=O)[C@@H](N)Cc1ccc(O)c(I)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 7/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
THRA P10827 4/20 0.52
LMNA P02545 3/20 0.52
PPARG P37231 2/20 0.52
CYP2D6 P10635 1/20 0.52
TSHR P16473 1/20 0.52
GABRP O00591 1/20 0.52
GABRD O14764 1/20 0.52
ABCB11 O95342 1/20 0.52
F2 P00734 1/20 0.52
PCNA P12004 1/20 0.52
GABRA1 P14867 1/20 0.52
GABRB1 P18505 1/20 0.52
GABRG2 P18507 1/20 0.52
GABRB3 P28472 1/20 0.52
ADORA1 P30542 1/20 0.52
GABRA5 P31644 1/20 0.52
GABRA3 P34903 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9647408 1.00 THRB (0.52) THRBMEN1KMT2ATHRALMNA
Hydrochloric Acid SCHEMBL9662459 0.99 ALDH1A1 (0.53) THRBMEN1KMT2ATHRALMNA
Hydrochloric Acid SCHEMBL7673388 0.99 ALDH1A1 (0.53) THRBMEN1KMT2ATHRALMNA
SCHEMBL12866354 0.88 MEN1 (0.63) THRBMEN1KMT2ATHRALMNA
SCHEMBL3683264 0.87 THRB (0.52) THRBMEN1KMT2ATHRALMNA
SCHEMBL8160664 0.87 THRB (0.51) THRBMEN1KMT2ATHRALMNA
SCHEMBL3683267 0.87 THRB (0.52) THRBMEN1KMT2ATHRALMNA
SCHEMBL12866377 0.87 THRB (0.58) THRBMEN1KMT2ATHRALMNA
SCHEMBL27294832 0.87 THRB (0.53) THRBMEN1KMT2ATHRALMNA
Melevodopa SCHEMBL8470037 0.86 ALOX15 (0.66) MEN1KMT2ALMNAPPARGCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053249-B2 Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders PHILIPPE YVES-REMY SIMON (FR) 2021-07-06 US claimed
US-5155229-A Inhibit cholesterol biosynthesis, radioimmunoassay of pravastatin and its derivatives E. R. SQUIBB & SONS, INC. (US) 1992-10-13 US claimed
US-4857522-A Derivatives of pravastatin for inhibiting cholesterol biosynthesis E. R. SQUIBB & SONS, INC. (US) 1989-08-15 US claimed
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US disclosed
US-20260049178-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-02-19 US disclosed
WO-2025024422-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-01-30 WO disclosed
US-20240335568-A1 RADIOPAQUE POLYSACCHARIDE HYDROGELS AND METHODS OF MAKING THE SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-10-10 US disclosed
US-11702452-B2 Process for making arylomycin ring analogs GENENTECH, INC. (US) 2023-07-18 US disclosed
US-11702452-B2 Process for making arylomycin ring analogs GENENTECH, INC. (US) 2023-07-18 US disclosed
US-11702452-B2 Process for making arylomycin ring analogs GENENTECH, INC. (US) 2023-07-18 US disclosed
US-20220056078-A1 PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS GENENTECH, INC. (US) 2022-02-24 US disclosed
WO-1999006433-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO disclosed
WO-1998022493-A2 N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO disclosed
US-5155229-A Inhibit cholesterol biosynthesis, radioimmunoassay of pravastatin and its derivatives E. R. SQUIBB & SONS, INC. (US) 1992-10-13 US disclosed
US-5096694-A Chloromethyl- and radioactive iodine substituted hydroxygonane derivatives IRE-CELLTARG S.A. (BE) 1992-03-17 US disclosed
US-5047549-A Radioimmunoassay E. R. SQUIBB & SONS, INC. (US) 1991-09-10 US disclosed
US-4857522-A Derivatives of pravastatin for inhibiting cholesterol biosynthesis E. R. SQUIBB & SONS, INC. (US) 1989-08-15 US disclosed
EP-0310645-A1 COMPOUNDS USEFUL PARTICULARLY FOR RADIOTHERAPY OR IMAGING OF CANCER. IRECELLTARG S A (BE) 1989-04-12 EP disclosed
WO-1988007986-A2 COMPOUNDS USEFUL PARTICULARLY FOR RADIOTHERAPY OR IMAGING OF CANCER IRE-CELLTARG S.A. (BE) 1988-10-20 WO disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335568-A1 RADIOPAQUE POLYSACCHARIDE HYDROGELS AND METHODS OF MAKING THE SAME CD44, ALG1, CA13 THRB 4074/4885MEN1 1073/4885KMT2A 3066/4885
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS KLK3, BRDT, BPHL THRB 955/4885MEN1 1567/4885KMT2A 2276/4885
US-20260049178-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM NPPA, MACF1, IGF1R THRB 651/4885MEN1 1139/4885KMT2A 774/4885
US-11702452-B2 Process for making arylomycin ring analogs RRS1, GLRA1, MRPL21 THRB 638/4885MEN1 3392/4885KMT2A 3875/4885
US-11053249-B2 Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders PSMB5, PSMB1, PSMB11 THRB 3241/4885MEN1 1547/4885KMT2A 2078/4885
US-20220056078-A1 PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS RRS1, GLRA1, MRPL21 THRB 638/4885MEN1 3392/4885KMT2A 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.